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ABSTRACT 
Large-scale cancer genomic studies have revealed that the genetic heterogeneity of the 
same type of cancer is greater than previously thought. A key question in cancer genomics is the 
identification of driver genes. Although existing methods have identified many common drivers, 
it remains challenging to predict personalized drivers to assess rare and even patient-specific 
mutations. We developed a new algorithm called DawnRank to directly prioritize altered genes 
on a single patient level. Applications to TCGA datasets demonstrated the effectiveness of our 
method. We believe DawnRank complements existing driver identification methods and will 
help us discover personalized causal mutations that would otherwise be obscured by tumour 
heterogeneity. Source code can be accessed at http://bioen-
compbio.bioen.illinois.edu/DawnRank/. 
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CHAPTER 1 
INTRODUCTION 
Recent advances in next-generation sequencing (NGS) technologies have provided us with an 
unprecedented opportunity to better characterize the molecular signatures of human cancers. The 
critical challenge facing cancer genomics today is to analyze and integrate such information in 
the most efficient and meaningful way to advance cancer biology, and then to translate that 
knowledge to clinic [1, 2]. A key question in cancer genomics is how to distinguish “driver” 
mutations, which contribute to tumorigenesis, from functionally neutral “passenger” mutations 
[3]. The most basic approach is to categorize mutations based on recurrence, i.e., the most 
commonly occurring mutations are more likely to be drivers [4, 5], or by comparing mutation 
rates in individual genes based on an empirically derived background mutation rate, such as 
MutSig [6] and MuSiC [7]. Machine learning based approaches use existing knowledge to help 
identify drivers. For example, CHASM utilizes random forest to classify driver mutations using 
alterations trained from known cancer-causing somatic missense mutations [8]. There are several 
recent methods that use additional information to help predict driver genes and driver pathways. 
CONEXIC was developed to integrate copy number change and gene expression data to identify 
potential driver genes located in regions that are amplified or deleted in tumors [9]. Network and 
pathway-based approaches have become one of the most promising methods to understand 
drivers due to their ability to model gene-gene interactions by aggregating small effect sizes from 
individual genes. MEMo and Dendrix rely on predicted mutual exclusivity of driver mutations 
within pathways or subnetworks [10, 11]. MEMo utilizes driver cliques based on known 
pathways with mutually exclusive mutations in the patient cohort, whereas Dendrix identifies 
subnetworks (de novo) with potential driver activity as having high coverage and high mutual 
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exclusivity. Another method, PARADIGM-Shift was developed to utilize pathway-level 
information along with other features (such as expression, methylation, copy number) to infer 
gain and loss of function for mutations. PARADIGM-Shift works best with small pathways with 
specific genes of interest, i.e., focus genes [12]. DriverNet classifies driver mutations as 
mutations that propagate outlying downstream differential expression in the transcriptional 
regulatory network [13]. More recently, TieDIE [14] was developed to find small cancer driver 
pathways within a large super-pathway to connect genomic alterations with transcriptomic 
changes, MAXDRIVER [15] was proposed to identify driver genes by integrating multiple 
omics data and heterogeneous networks, and VarWalker [16] was developed to construct cancer-
specific mutation networks to assist driver identification in a patient cohort. However, the scope 
of these methods is still limited. Most existing methods such as MEMo, Dendrix, and DriverNet 
require a large number of patient samples to generate reliable results and lack the ability to 
discover rare and patient-specific drivers. Other methods such as PARADIGM-Shift are 
designed to determine drivers in small pathways and often require detailed previous knowledge 
of specific pathways and focus genes to operate effectively. New methods are needed to identify 
novel and rare drivers when we do not have much prior knowledge of the tumor. 
 It is now acknowledged that individual tumors of the same type are highly heterogeneous and 
have diverse genomic alterations [2, 17]. This stems from the “long-tail phenomenon” which 
states that cancer mutations are characterized by a small number of frequently mutated genes and 
a large number of infrequently mutated genes [18, 19]. Discovering rare drivers in the long tail of 
genetic alterations remains difficult. Therefore, we urgently need methods to assess the impact of 
patient-specific and rare mutations from individual tumor samples in order to elucidate 
personalized molecular drivers.  
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In this work, we introduce a new method called DawnRank that detects driver genes using data 
from a single patient sample. By only using data from an individual patient sample rather than a 
large cohort, we identify drivers in a personalized fashion. The single patient approach classifies 
drivers regardless of mutation frequency, thereby allowing us to focus on rare (infrequent) 
drivers. DawnRank ranks potential driver genes based on their impact on the overall differential 
expression of its downstream genes in the molecular interaction network. Mutated genes with 
higher ranking are more likely to be drivers. Our method builds on the DriverNet rationale that 
the impact of a potential driver gene can be determined by its effect on the genes that are 
regulated by it. However, unlike DriverNet, DawnRank can be applied to a single patient at a 
time. It is also important to note that our approach differs from the aforementioned 
PARADIGM-Shift. The small-scale network approach of PARADIGM-Shift works well when 
the user has a target pathway and genes in mind, but is not applicable in determining rare driver 
genes distributed across multiple pathways with a more comprehensive gene network. 
DawnRank differs from MEMo and Dendrix as the scope of DawnRank is to determine 
individual driver genes rather than driver pathways. Although CONEXIC also utilizes pathway 
information to identify important CNVs, DawnRank has a more generalized framework to assess 
the impact of both mutations and CNVs at the individual patient level. Such a patient-specific 
framework also makes DawnRank different from methods such as MAXDRIVER and 
VarWalker. DawnRank also differs from TieDIE, which predicts subnetworks of interlinking 
genes that highlight cancer specific subnetworks, whereas DawnRank predicts individual driver 
genes. 
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CHAPTER 2 
METHODS 
The DawnRank method ranks mutated genes in a single patient according to their potential to be 
drivers. DawnRank requires the knowledge of a gene interaction network, somatic genomic 
alterations from the patient’s cancer genome, and the differential gene expression profile 
between the cancer transcriptome and normal transcriptome. The overview of DawnRank is in 
Figure 1. Our method ranks genes according to their impact on the perturbation of downstream 
genes, i.e., a gene will be ranked higher if it causes many downstream genes, directly or 
indirectly in the interaction network, to be differentially expressed. DawnRank views the gene 
network as a directed graph. We adopted the random walk approach used in PageRank [20, 21] 
to model this process iteratively. The framework effectively reflects the observation from 
previous works that mutations in genes with higher connectivity within the gene network are 
more likely to be impactful. In each iteration, a node in the network can either, with a probability 
1 − 𝑑 (d is called damping factor, which we defined in a new way. See below.), revert back to 
stay at the same node, or with a probability 𝑑 to walk randomly to a downstream node, which 
symbolizes the impact a particular gene has on its downstream neighbors. Our method depends 
on three parameters: the differential gene expression, the interaction network as a directed graph, 
and the damping factor. These three parameters along with genomic alterations form the key 
components of our model to determine drivers in individual patient samples. The output of the 
rank describes gene’s overall impact. In order to produce a more readable form of the rank, we 
converted the rank into percentile form to get the relative order of the genes in the rest of this 
paper.  
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2.1 DawnRank Algorithm 
 
In DawnRank, a gene will possess a higher impact score (i.e., rank) if the gene is highly 
connected to differentially expressed downstream genes (directly and indirectly connected). 
Driver genes tend to display a high-degree of connectivity within the gene network [22, 23]. For 
example, using the number of outgoing edges alone, known driver genes as classified by the 
Cancer Gene Census (CGC) [24] have a mean and median of 31.45 and 12 outgoing edges, 
respectively, whereas genes not typically classified as drivers (not in CGC) have a mean and 
median of 17.73 and 3 outgoing edges, respectively. The higher number of outgoing connectivity 
of known driver genes suggests that the PageRank model would be appropriate to prioritize 
driver genes based on their impact in the gene interaction network. PageRank has had several 
adaptations in genomics. GeneRank utilized PageRank to rank the importance of genes in a 
molecular network [25]. PageRank derivatives (such as SPIA [26]) have also been used to 
analyze pathway-level importance. More recently, it was utilized to predict clinical outcome of 
cancer patients based on gene expression [27] and to assist subtype identification [28]. Such 
approaches also show similarity in nature to modeling network impact as a heat diffusion process 
as used in HotNet [29] and TieDIE [14]. DawnRank builds on the original PageRank algorithm 
by providing a way to model a network’s directionality with more stable rankings by utilizing 
dynamic damping factors (see below). 
 DawnRank views the gene network as a directed graph. Let N be the number of nodes (in 
our case, genes) in the directed graph, and A be the adjacency matrix representation of the graph, 
a 0-1 matrix (if node i links to j, then 𝐴#$ = 1). Note that the current 0-1 adjacency matrix can be 
naturally extended to consider weighted edges to further distinguish different gene-gene 
interactions.  
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We define the rank of each gene iteratively: 
𝑟$()* = (1 − 𝑑$)𝑓$ + 𝑑$ 𝐴$#𝑟#(𝑑𝑒𝑔#2#3* , 1 ≤ 𝑗 ≤ 𝑁 (1) 𝑟(	is the rank in the 𝑡(: iteration. The output of the rank describes a gene’s overall impact on the 
network: the higher the rank, the higher the impact of the gene. 𝑑 is the damping factor, a 
parameter representing the extent to which the ranking depends on the structure of the graph. In 
DawnRank, the damping factor is individualized based on gene connectivity (discussed below). 𝑓 is the prior probability of the gene which we set to the absolute differential expression. The 
absolute differential expression is the absolute value of the difference of the log scale tumor and 
normal expression values. The 𝑑𝑒𝑔# = 𝐴$#2$3*  is the in-degree of i, or the number of incoming 
nodes to i. This differs from the original PageRank definition of 𝑑𝑒𝑔#, which was the out-degree 
of i. A webpage’s PageRank is dependent on the rank of the webpages that link to it (incoming 
edges), whereas our gene’s rank is dependent on the rank of the genes that it links to (outgoing 
edges).  
The zero-one gap problem refers to the potential pitfall that assigns biased ranks to some 
nodes [30]. When trying to rank nodes with 0 incoming edges, known as “dangling nodes”, the 𝑑𝑒𝑔#	will be 0, arising to a divide-by-zero error. In our real gene network data, 15.5% of all 
genes do not have any incoming edges. The initial PageRank algorithm attempts to handle the 
problem by setting the damping factor to be 0 for such genes, while using the damping factor 
0.85 for all other nodes. If we use this approach, the ranks of genes with no incoming edges will 
be based solely on its differential expression (and not the network structure). However, this 
correction in itself causes a large gap in the damping factor for genes with 0 and 1 incoming edge 
(Supplementary Figure C3). This large gap in the damping factor can cause a drastic change in 
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the ranking of the gene when an incoming edge is added to the gene which in turn may cause 
unstable rankings [30]. An unstable ranking system is especially concerning to gene network 
data, as it is still not a complete representation of all interactions among genes [31]. Therefore, 
small modifications and additions to certain gene interactions may significantly alter the rankings 
of potential drivers. To address this problem, we utilize dynamic damping factors [30], where 
each gene possesses an individualized damping factor based on the number of incoming edges to 
that gene (Eq. 2). As the number of incoming edges increases, the damping factor gradually rises 
to incorporate more connectivity information into the ranking of the gene, therefore no large gap 
is observed from 0 in-degree and 1 in-degree (see Supplementary Figure C3). 
𝑑# = 	 𝑑𝑒𝑔#𝑑𝑒𝑔# + 𝜇 (2) 
The parameter 𝜇 follows a Dirichlet prior trained from maximizing the values of 𝜇 over 100 
random samples. We selected the 𝜇 value of 3 because it had the highest average DawnRank 
scores for known drivers in CGC (see Supplementary Materials for more details on how 𝜇 was 
trained). Overall, the dynamic damping factor mitigates the large change in the damping factor in 
nodes with 0 and 1 incoming edges by gradually increasing the damping factor as the gene’s in-
degree increases, thereby creating more reliable and more stable rankings. A toy example is in 
the Supplementary Figure C2. We also show that DawnRank performs more reliably with a 
dynamic damping factor than a static damping factor on the TCGA datasets (see Supplementary 
Figure C1). 
In addition to the iterative version of DawnRank, the method can also be presented in 
matrix form: 𝑟()* = (1 − 𝑑)𝑓 + 𝑑𝑀×𝑟( (3) 
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where 𝑟(,	𝑑, and 𝑓 are N×1 matrices to represent the rank, gene-specific damping factor, and the 
gene expression, respectively, and 𝑀 is the transition matrix defined by: 
𝑴 =	 𝐴*,*𝑑𝑒𝑔* ⋯ 𝐴*,@𝑑𝑒𝑔@⋮ ⋱ ⋮𝐴@,*𝑑𝑒𝑔* ⋯ 𝐴@,@𝑑𝑒𝑔@  (4) 
DawnRank converges when there is no longer a significant update in the ranks. This is 
when the magnitude of the difference of the ranks between time 𝑡 + 1 and the previous time 
point 𝑡 falls below a small 𝜀, which we set to 0.001, the same value suggested by [30]. 
DawnRank also stops when no solution is present after a maximum number of iterations, which 
we set at 100. In practice, DawnRank always converges for any reasonable µ between 0.01 and 
20 within 20 iterations. Nonetheless, there are corner cases at low damping factors (µ < 10G*H) 
where DawnRank either does not converge or converges very slowly. A detailed discussion of 
the convergence of DawnRank can be found in the Supplementary Materials. 
2.2 Condorcet Voting for Rank Aggregation 
To aggregate the rankings of genes from individual patient samples to determine the most 
impactful drivers in a population (e.g., known drivers for the same type of cancer or a specific 
sub-type), DawnRank applies a modified version of the Condorcet method [32]. The Condorcet 
method is a voting scheme in which “voters” vote for the best “candidate” by submitting a rank-
ordered list of candidate preferences. The list of preferences is allowed to be either partial or full. 
The Condorcet method then selects a winning candidate by comparing every possible pair of 
candidates A and B and determining a “winner” by comparing the number of voters that 
preferred A to B and vice-versa. We applied the Condorcet method to the personalized rankings 
of genes to determine aggregate ranking of genes in a patient population. 
9	
	
Although the Condorcet method is built to handle partial voting lists, one difficulty of 
implementing the Condorcet method is the lack of patient samples that possess the commonly 
mutated genes. Many pairwise comparisons are missing for many gene combinations due to the 
lack of patients that have mutations in both genes simultaneously. However, since DawnRank 
can output a ranking as an impact score for all genes regardless if a gene is mutated, we 
evaluated pairwise comparisons of two genes based on patients with a mutation in at least one of 
the two genes. This approach avoids the use of non-mutated gene comparisons to calculate the 
aggregate score of genes, as the objective of DawnRank is to determine the altered genes that are 
the most impactful. However, since mutation recurrence is an important factor in detecting 
common drivers, we also implemented a penalty heuristic,	𝛿, a number between 0 and 1 in our 
approach to lower the ranking of a gene in a pairwise comparison that is not mutated. This 
penalty allows us to rank aggregate frequent drivers based on both impact and frequency. PairwiseWinner 𝐴, 𝐵 = 𝐴		if	𝛿(𝐴)×𝑅𝑎𝑛𝑘(𝐴) > 𝛿(𝐵)×𝑅𝑎𝑛𝑘(𝐵)	𝐵																													otherwise  (5) 
where  𝛿(𝐴) = 𝛿												if	𝐴	is	NOT	mutated1																					if	𝐴	is	mutated  (6) 
We used the output from DawnRank, which we converted to percentile rank format, to represent 
the ranking of the gene. The penalty heuristic lowers the value of a non-mutated gene when 
comparing it against a mutated gene. This heuristic serves as both a means to prevent a rare 
mutation that is impactful in one patient from winning all pairwise comparisons (akin to a 
candidate winning just because one and only voter that voted for it ranked it higher than any 
other candidate) and to prevent a low impact, high frequency mutation from winning a pairwise 
comparison against high-impact genes that are not frequently mutated (akin to an unpopular 
candidate winning just because many voters had a low-preference vote for that candidate). We 
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selected 𝛿 by running DawnRank over 100 random patient samples for various instances of 𝛿 
between 0 and 1 and calculating the precision with respect to CGC genes (see Supplementary 
Materials). We found 𝛿 to be 0.85. 
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CHAPTER 3 
RESULTS 
We applied DawnRank to TCGA datasets. We first showed that DawnRank outperforms two 
recent pathway-based methods DriverNet and PARADIGM-Shift. We also showed that 
DawnRank produces reliable results as compared to cohort-based approaches CHASM and 
OncodriveFM. We then used the results of DawnRank to determine both potential novel drivers 
(new genes mutated frequently), and more importantly, potential rare and personalized drivers 
that previously could not be assessed by other methods. We also applied the method to study 
breast cancer subtypes and found that the amount of predicted rare drivers has a strong 
correlation with the degree of genetic heterogeneity in different breast cancer subtypes.  
3.1 Datasets and Network 
We applied DawnRank to 512 glioblastoma multiforme (GBM) samples, 504 breast cancer 
(BRCA) samples, and 572 ovarian cancer (OV) samples in TCGA. The datasets we used in this 
work include gene expression and coding-region mutation data for three cancer types generated 
by TCGA [33-35]. The data was accessed on May 20, 2013. The mutation data we used included 
non-synonymous point mutations and insertions and deletions (indels) in coding regions.  
We built the gene interaction network used in DawnRank using a variety of sources, 
including the network used in MEMo [10] as well as the up-to-date curated information from 
Reactome [36], the NCI-Nature Curated PID [37], and KEGG [38]. The MEMo network 
consisted of inferred gene-interaction from sources of information such as protein interactions, 
gene co-expression, protein domain interaction, and text-mined interaction described by [39]. To 
aggregate all of the networks together, all redundant edges were collapsed to single edges. We 
included self-loops within the network to account for auto-regulation events [40]. The resulting 
12	
	
aggregate network consisted of 11,648 genes and 211,794 edges, and can be downloaded from 
our supplementary website. 
To help evaluate the quality of our results, we obtained a list of 487 known driver genes 
from the well-studied cancer gene database, CGC [24]. Additionally, we also compared the 
quality of our results to the Pan-Cancer drivers [41], a driver gene list built using results from 
well known cohort-based methods over twelve tumor types. In practice, there is no gold standard 
of known drivers. However, well-curated cancer gene databases such as CGC and the Pan-
Cancer study provide an approximate benchmark of known drivers [13, 42]. 
3.2 Comparison to Previous Methods 
3.2.1 DawnRank outperforms pathway-based methods DriverNet and PARADIGM-Shift 
We evaluated the performance of DawnRank’s ability to identify known drivers and compared it 
with DriverNet and PARADIGM-Shift. As mentioned above, we utilized CGC as an 
approximate benchmark of known drivers. Note that here we implicitly assume that all non-
synonymous mutations in driver genes are potential driver mutations if they are selected by a 
method. We performed two separate comparisons. (1) We compared DawnRank to DriverNet 
over a large network in order to evaluate the performance of the two methods using a large 
human interaction network (which PARADIGM-Shift is not able to work with practically). (2) 
We compared DawnRank to PARADIGM-Shift and DriverNet over a smaller, but well-
annotated gene network based on KEGG in order to determine the effectiveness of the three 
algorithms in smaller networks. The network used in the first comparison was the same network 
described earlier. The network used in the second comparison was a smaller network built from 
the aggregation of the KEGG cancer pathways with 1,492 gene nodes and 8,070 edges. We ran 
DriverNet version 1.0.0, defining a differentially expressed gene using their default settings of 2 
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standard deviations (http://www.bioconductor.org/packages/release/bioc/html/DriverNet.html), 
and we ran PARADIGM-Shift version 0.1.9 using the suggested global-rank transformation for 
expression data (http://sysbio.soe.ucsc.edu/paradigm/tutorial/). To facilitate the comparison, we 
applied the Condorcet rank aggregation (see Methods) for the DawnRank scores based on 
individual patient samples to provide the consensus population-level driver scores. For each 
comparison, we used the following three measures (Precision, Recall, and F1-Score): 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = (#	Mutated	Genes	found	in	CGC) ∩ (#	Genes	found)(#	Genes	found)  
𝑅𝑒𝑐𝑎𝑙𝑙 = (#	Mutated	Genes	found	in	CGC) ∩ (#	Genes	found)(#	Mutated	Genes	found	in	CGC)  
𝐹*	𝑆𝑐𝑜𝑟𝑒 = 2× 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛×𝑅𝑒𝑐𝑎𝑙𝑙𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑅𝑒𝑐𝑎𝑙𝑙 
(7) 
Precision, recall and F1 scores were based on the top N genes. We first evaluated the 
performance between DawnRank and DriverNet. In general, DawnRank outperforms DriverNet 
in all three cancer datasets with respect to CGC (Figure 2). Although DriverNet performs 
comparably in ranking the top genes in GBM, it has poorer performance in OV and BRCA. A 
potential explanation of the difference may lie in the total number of mutations in the three 
cancer datasets. GBM had 5,478 mutations over 599 genes, while OV had 13,520 mutations over 
4,968 genes and BRCA had 11,900 mutations over 5,205 genes. The numbers indicate that there 
may be more passenger mutations in BRCA and OV and DawnRank is less affected by noise 
than DriverNet. An illustration of this is DriverNet’s ranking of the gene TTN as a top 5 driver in 
both BRCA and OV. TTN is the longest gene in the human genome and recent TCGA analysis 
has suggested that that higher mutation rate in TTN is likely to be artifacts [34]. TTN was not 
ranked among the top 60 genes in any cancer according to DawnRank. We then evaluated the 
performance of DawnRank, PARADIGM-Shift, and DriverNet using the smaller KEGG 
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network. Overall, DawnRank outperforms both DriverNet and PARADIGM-Shift in terms of 
precision, recall, and F1 scores using CGC as a standard (Figure 3) or the Pan-Cancer results as a 
standard (Supplementary Figure C11). In BRCA, although some known drivers such as TP53 
and ATM were detected by multiple methods, DawnRank detected important known driver genes 
in the top 10 such as CDH1, PIK3R1, and BRCA1 in breast cancer which were not detected by 
either PARADIGM-Shift or DriverNet as top ranking drivers. 
In addition to its ability to more precisely identify known driver genes at the entire patient 
population level, DawnRank also has an advantage of obtaining high-quality results from a much 
smaller patient cohort. To evaluate this ability, we applied DawnRank to random subsets of the 
patient cohort from GBM, OV, and BRCA from 10, 20, 50, and 100 patients to determine the 
precision at which DawnRank identifies known drivers in its top 30 results. We compared these 
results with that of DriverNet using the same patient subsets. The mean of the precision scores 
after ten runs is presented in Figure 4. We found that even with a small patient cohort, 
DawnRank can still perform reasonably well, much better than DriverNet. Even though 
DawnRank does not perform as well with a sample of 10 as it can with the entire dataset, the 
average DawnRank precision at 10 samples is comparable to the DriverNet precision using the 
entire cohort. Our results suggest that DawnRank is able to identify known drivers even with a 
small number of samples. 
 
3.2.2 DawnRank achieves reliable results as compared to cohort-based approaches CHASM and 
OncodriveFM 
In addition to comparing DawnRank to the pathway-based approaches of DriverNet and 
PARADIGM-Shift, we compared DawnRank to non-pathway-based approaches as well. We 
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compared DawnRank with CHASM [8] and OncodriveFM [43]. We ran CHASM version 3.0 
using CRAVAT [44] with the cancer driver analysis mode (http://www.cravat.us/), and we ran 
OncodriveFM using the IntOGen Mutation Analysis interface using SIFT, Polyphen2, and 
Mutation Assessor data (http://www.intogen.org/web/mutations/v04/analysis). Both CHASM 
and OncodriveFM can rank genes from most likely drivers to least likely ones. Like in 
DawnRank, we evaluated all non-synonymous mutations and evaluated each method using 
precision-recall metrics in comparison to CGC. The results (Supplementary Figure C10) show 
that DawnRank performs comparably to both CHASM and OncodriveFM. These results also 
demonstrate that the personalized approach of DawnRank can achieve reliable results at the 
cohort level.  
3.3 Discovering New and Personalized Drivers 
In this section, we use DawnRank to identify driver genes that may not have been classified as 
drivers by other methods. We discuss such driver genes determined by DawnRank in two main 
categories: general novel drivers, and personalized drivers (we are mostly interested in 
personalized rare drivers).  
• A general novel driver is a recurrent driver that has not been classified as a driver gene. 
Here we define novel drivers as genes that satisfy the following requirements: (1) Highly 
ranked (genes that have an aggregate rank in the top 30 of driver genes based on the 
patient cohort), which means it is considered as driver in multiple samples; (2) Recurrent 
(alteration frequency >2% in the patient cohort); (3) Not previously classified as a driver 
by CGC.  
• A personalized driver is a gene predicted to be a driver for specific patients. Here we 
define personalized drivers as drivers classified as significant using DawnRank’s 
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maximally selected rank statistics cutoff (explained later) and as drivers that display 
higher than expected rankings under the Chauvenet’s criterion for detecting outliers. In 
other words, personalized driver genes could be recurrently mutated in multiple samples, 
but they are only ranked high enough to be considered as drivers in specific samples. We 
are particularly interested in rare drivers, as rare drivers would be obscured by the long 
tail phenomenon of cancer mutations. Personalized drivers mutated in less than 2% of 
patients will be considered personalized rare drivers.  
3.3.1 Discovering Novel Drivers with Coding Mutations 
Using the criteria listed above to detect novel drivers, we used the aggregate DawnRank score to 
select genes with coding mutations that were considered novel drivers. In GBM, we found 
several consistently high-ranking potential novel driver genes. Of them, TGFBR2, HIF1A, and 
FOXO3 are the most promising. These genes are highly rank, frequently mutated, and are 
involved in several cancer functions and pathways. TGFBR2 is a transforming growth factor 
whose function is to regulate cell division signals and inhibit cell division [45]. TGFBR2 is the 
third-ranked driver in terms of Condorcet aggregate score, and it is altered in 18.7% of GBM 
patient samples. TGFBR2 is classified as a potential tumor suppressor (it shows decreased 
expression in GBM samples), and it is involved in many pathways to cancer including TGFβ 
signaling, HTLV infection, and Hippo signaling [46]. HIF1A is a hypoxia inducing factor that 
has been shown to be necessary for the survival of cancer stem cells in gliomas [47]. HIF1A is 
involved in mTOR pathway, which regulates nutrient sensing for cell growth, which could be 
responsible for cell growth and metastasis in cancer. HIF1A is ranked as the fourth most 
impactful driver in GBM, and it is mutated in 13.4% of GBM patient samples [48]. FOXO3 is 
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the eighth ranked gene. It is a common phosphorylation target of AKT and ERK, and is a key 
trigger for apoptosis in the PIK3/AKT pathway [49]. 
In OV and BRCA, there were fewer candidate novel drivers than GBM, however, we 
found two genes that show strong potential to become novel drivers: PDPK1 in OV and CENPE 
in BRCA. PDPK1 is a phosphoinositide dependent protein kinase-1 that interacts with a crucial 
driver gene AKT1, and together their signaling plays a critical role in activating proliferation and 
survival pathways within cancer cells such as the PIK3/AKT pathway and the mTOR pathway 
[50, 51]. PDPK1 is ranked second in OV and is mutated in 5.4% of OV samples. The mutation in 
PDPK1 itself also suggests an important impact in the functionality of the protein binding. For 
example, in sample TCGA-13-0751, the mutation is in a Glycine to Arginine substitution near a 
hairpin loop in the middle of the protein (Supplementary Figure C6). The amino acid change 
from G to R changes the dynamic of the protein structure by replacing a non-polar amino acid 
with a positively charged amino acid, which may change the binding interaction with the 
negatively charged substrate phosphatidylinositol-3,4,5-trisphosphate, which in turn may affect 
the phosphorylation and activation of at least 24 kinases [52].  
In BRCA, a potential novel driver we found is CENPE. CENPE is a centromere-associated 
protein that contributes to mechanics of microtubule-chromosome interactions with mitotic 
checkpoint. Overexpression of CENPE can lead to excessive cell growth and contribute to tumor 
proliferation [53]. CENPE is ranked 26-th in DawnRank. We observed that it is highly 
overexpressed in tumor samples. CENPE is interesting as it is ranked differently among different 
subtypes of breast cancer. All but one of the mutations in CENPE was in Luminal B or Basal 
subtype. The Basal subtype mutations had the highest average ranking in the 95.2 percentile and 
the average Luminal B subtype mutations ranked lower in the 90.9 percentile, whereas the 
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Luminal A mutation was much less significant with a ranking in the 78.3 percentile. This shows 
that even though CENPE has mutations in multiple subtypes, it may harbor different driver 
potentials in different subtypes.  
3.3.2 Discovering Novel Drivers with Copy Number Changes 
We then applied DawnRank to examine the role of CNVs in the three cancer types used in this 
study. We included genes that displayed at least a two-fold change in copy number change and 
also had a corresponding change in expression. We treated CNV events in a similar fashion as 
coding mutations to prioritize the genes with an amplification and deletion and then determined 
the most impactful CNVs. In addition to known driver genes with CNVs, we also identified 
novel driver CNVs not in CGC (Supplementary Figure C7). 
In GBM, known CNV drivers (based on CGC) include the amplification of some well-
known driver genes such as EGFR, PDGFRA, and MYC and the deletions of MLLT3 and ANK3. 
A potential novel driver CNV is the amplification of SEC61G. SEC61G is a proto-oncogene that 
is required for tumor cell survival [54]. SEC61G is altered in 14.3% of GBM cases and it is 
ranked 17-th among CNVs. ELAVL2 is a potential tumor suppressor gene whose function is to 
stabilize and control nervous-specific binding proteins [55]. ELAVL2 is altered in 6.7% of GBM 
cases and is ranked 2nd among CNVs in GBM. In OV, many known drivers are amplifications 
such as CCNE1 and KRAS and deletions such as MAF or PIK3R1. An example of a novel 
amplification is FZD5, a “frizzled” gene that has a strong co-expression event with the Wnt 
signaling pathway in ovarian cancer [56]. FZD5 is altered in 2.9% of OV cases and it is ranked 
9th among CNVs in OV. In BRCA, known driver CNVs include amplifications in CCND1, 
MYC, GATA3 and EGFR and deletions in MAF. An example of a novel amplification event in 
BRCA is PAK1, which is a breast cancer oncogene that activates MAPK and MET signaling 
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pathways [57]. PAK1 is the 3rd ranked gene with CNVs, and it is altered in 2.4% of the BRCA 
patient samples.  
3.3.3 Discovering Personalized Drivers  
In this section, we discuss the personalized scope of DawnRank by demonstrating its ability to 
determine personalized novel and rare drivers. The main aspect that distinguishes DawnRank 
from existing programs is the ability to discover rare and even patient-specific drivers. Even if a 
gene is altered only in a single patient, DawnRank will still be able to evaluate the impact of that 
alteration. We determined such personalized drivers using the “maximally rank statistics” 
method. This method classifies alterations as “drivers” and “non-drivers” by assigning a cutoff 
that maximizes the number of known driver genes (genes in CGC) ranking higher than the 
cutoff). Altered genes in the individual patient with a ranking higher than the cutoff would be 
described as personalized drivers. The average cutoff for GBM, OV, and BRCA was 98.1, 92.8, 
and 92.2, respectively (measured in percentile rank). We specifically looked for genes that have 
not been classified as a driver in CGC and genes that have a significantly higher than expected 
rank in specific patients. A rank is considered significantly high in a patient if the rank is 
considered as an outlier under Chauvenet’s criterion for outlier detection.  
In our case, a gene is considered to be a rare driver if the gene is both classified as a driver 
using the above criteria, and it is mutated in only a small number of patients (<2%). We selected 
genes that fit the above criteria to discover potential personalized drivers: genes that labeled as 
significant from the maximally-selected rank statistics and genes that ranked higher in specific 
patients according to the Chauvenet’s criterion. These selection criteria yielded in 26 potential 
personalized drivers in GBM (10 from mutations, 16 from CNV), 56 potential personalized 
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drivers in BRCA (20 from mutations, 36 from CNV), and 77 potential personalized drivers in 
OV (26 from mutations, 51 from CNV) (Figure 5A and Supplementary Figures S8 and S9).  
We found 26 potential personalized drivers in GBM. Of these genes, we found that several 
of the candidate driver genes were involved in important known cancer pathways. Using KEGG 
to map genes to pathways [46], mutations in three interferon receptor genes IFNA14, IFNW1, 
and IFNA17 belong to multiple pathways that have significant impact on cancer, including the 
Cytokine-Cytokine receptor pathway and the JAK/STAT pathway. Cytokines are important 
factors in tumor cell control as they are key players in inflammatory and immune response [58]. 
The JAK/STAT is a related pathway activated by the binding of cytokines to its receptor. The 
pathway is involved in inflammation, proliferation, and invasion/migration [59]. In either case, 
IFNA14, IFNW1, and IFNA17 are interferon receptor genes that may interact with genes such as 
TP53 to induce apoptosis of cancer cells [60]. Both the Cytokine-Cytokine receptor pathway and 
the JAK/STAT pathway are common drug targets in GBM [58, 59], which could lead to the 
implications that IFNA14, IFNW1, and IFNA17 could be targeted. IFNA14, IFNW1, and IFNA17 
are mutated in 4.7%, 5.6%, and 4.5% of GBM patients, respectively. IFNA14 is ranked 
significantly higher than its average expected ranking in patients TCGA-32-1978 and TCGA-19-
2619 while IFNW1 and IFNA17 both have high-ranking mutations in the patient TCGA-28-1749. 
Although IFNA14, IFNW1, and IFNA17 are examples of personalized drivers, they are not 
personalized rare drivers. An example of a personalized rare driver is PITX2, which is altered in 
only 2 patients (0.4%). PITX2 is in the TGFβ signaling pathway, which can be targeted by cancer 
drugs such as decanoyl-RVKR chloromethylketone in GBM [61, 62].  
We found 77 potential personalized driver genes in OV, and like GBM, many of these 
genes fall under similar KEGG pathways. Figure 5A shows the list of personalized drivers in 
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OV. The most well represented KEGG pathways are the calcium signaling pathway and the 
MAPK signaling pathway. Calcium signaling is important in the regulation of cancer cell 
proliferation and/or apoptosis [63]. In OV, four alterations are present in the calcium signaling 
pathway: mutations in ADORA2B, CACNA1E, and ITPR3 along with a CNV for SLC8A1. Of 
these alterations, ADORA2B is often associated with cancer cell movement and metastasis, and it 
has been a drug target in other cancers [64]. The MAPK signaling pathway plays a role in 
communication with cell growth, and it can be targeted by cancer drugs such as MEK and RAF 
inhibitors [65, 66]. Genes mutated in the MAPK signaling pathway include CACNA1E, TRAF6, 
and DUSP16. The TRAF6 gene is especially interesting as it up-regulates HIF1A and has 
implications in tumor angiogenesis [67]. TRAF6 is another good example to demonstrate the 
power of DawnRank because it is mutated in only two patients, TCGA-13-1410 and TCGA-61-
1919, but DawnRank was still able to detect it as a rare driver. We looked into the TRAF6 
mutation further, including its connectivity in the network and the potential functional impact of 
the mutation (Figure 5B and C). We found that the mutation in TCGA-13-1410 is considered to 
have an important functional impact by MutationAssessor, affecting the MATH domain [68]. 
The mutation is located at a loop defining one wall of the binding site and projects its long side-
chain to directly contact the conserved aromatic residue in the peptide substrate, and it likely 
modulates its interaction with its receptors [69]. TRAF6 is also known to be involved in the NF-
κB pathway, which is related to poor outcomes in ovarian cancer [70].  
We found 56 potential rare drivers in BRCA. Unlike in GBM and OV, the distribution of 
rare drivers in BRCA seemed to spread out among different pathway with no major cancer 
pathway having more than two candidate rare drivers. Nevertheless, several important cancer 
pathways are highlighted in BRCA. One of them is the KEGG “Proteoglycans in Cancer 
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Pathway”. Proteoglycans bind to ligands and receptors that regulate tumor neoplastic growth and 
angiogenesis [71]. Alterations in genes coding for proteoglycans include ANK3 and FRS2. Of 
these, FRS2 is especially interesting due to both its scarcity (only one amplification event in all 
BRCA patients) and its function as a fibroblast growth factor whose amplification activates the 
FGFR2 [72]. It is also highly differentially expressed in the patient, having differential 
expression 3.21 standard deviations above normal. The calcium signaling pathway, like in 
ovarian cancer, also has multiple potential drivers in breast cancer. These genes include 
CACNA1B and GRIN2A. GRIN2A is a potential rare driver as it is mutated in 1.7% of BRCA 
patients but it has been known to be recurrent driver mutation in other cancers [73].  
3.3.4 Discovering Personalized Drivers  
We next looked at the distribution of the candidate rare drivers across breast cancer subtypes. We 
tested whether or not the rare drivers show different distribution among patients in the four major 
subtypes of breast cancer (Luminal A, Luminal B, Her2, and Basal-like). Although we used a 2% 
as a threshold to determine rare drivers so far, we further modeled the personalized drivers at low 
frequencies using cutoffs from 1% to 5% to better visualize the distribution of infrequent, 
personalized drivers in BRCA subtypes. As shown in Figure 6A, the distribution of the driver 
genes is not the same among subtypes. The most obvious contrast involves the Basal-like and 
Luminal A comparison. Basal-like samples tend to have more very rare drivers occurring in less 
than 1% of the cases and have much small number of drivers occur over 1%. Luminal A 
samples, on the other hand, have fewer drivers occurring in less than 1% of the samples, but as 
the cutoff increases, more Luminal A drivers can be found. A Chi-squared goodness of fit test 
confirms that the distribution of Basal and Luminal A breast cancers have very different 
distributions (p=0.015). This may suggest a fundamental difference in the genetic heterogeneity 
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of Basal-like and Luminal A breast cancers. The rare driver distribution of Basal-like cancer is 
also different from the frequency distribution of known driver genes (Figure 6).  
The distribution of known drivers and rare drivers may correspond to the genetic 
heterogeneity of breast cancer subtypes. Luminal A is an ER+ subtype with less heterogeneity 
and has been defined by its good prognosis. Patients with Luminal A subtype generally have the 
most favorable outcome and have a smaller chance of relapse when treated early [74, 75]. On the 
other hand, the Basal-like subtype, which mainly comprises of triple negative breast cancers, is 
difficult to treat due to tumor heterogeneity. Basal-like breast cancers are known to be more 
aggressive with poor prognosis [35, 76]. Based on our results, we found that Luminal A samples 
seem to have common drivers more than any other cancer type. The pattern in the Basal-like type 
is the opposite. There are more potential rare drivers in Basal-like samples than other subtype. 
This suggests that Luminal A breast cancers are driven more by common drivers while Basal-
like breast cancers are driven more by rare drivers. 
 Potential personalized rare driver alterations for Basal-like breast cancer include LGR5 
and BCL2L14. LGR5 is a CNV that is amplified and overexpressed in the Basal-like patient 
sample TCGA-AN-A0AT. LGR5 is necessary for the stimulation of basal cell growth in breast 
tissue [77]. BCL2L14 is a key regulator of cell apoptosis at the mitochondria level [78], and it is 
altered in the single Basal-like patient TCGA-AN-A0FJ. 
3.4 Implementation and Running time 
DawnRank was implemented in R. Using a network of 1,492 nodes and 8,070 edges and a cohort 
of the BRCA samples we used, we compared the run time of DawnRank, DriverNet, and 
PARADIGM-Shift on a computer with 16GB RAM and Intel i5-3317U processor. DriverNet 
was the fastest, with a runtime of 6 minutes. DawnRank completed the analysis in 9 minutes for 
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the main script and 12 minutes for the Condorcet rank aggregator. PARADIGM-Shift took 
approximately 15 hours to run. 
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CHAPTER 4 
DISCUSSION 
It is now acknowledged that individual tumors of the same type are highly heterogeneous and 
have diverse genomic alterations. Therefore, we urgently need novel methods to identify patient-
specific and rare drivers from individual tumor samples in order to elucidate personalized 
molecular mechanisms in different types of cancer. The goal of DawnRank is to integrate 
mutation data, gene expression, and network information to discover drivers in a personalized 
manner. We applied DawnRank to a large number of TCGA datasets. By comparing to previous 
studies, our results demonstrated the effectiveness of DawnRank: (1) Despite its single-patient 
scope, DawnRank detects common and known drivers with as much or more precision than 
existing methods. (2) We can identify rare and novel genes that are potential drivers to specific 
patients. We believe this method will complement existing driver identification methods and will 
help us discover potential personalized drivers. The application to breast cancer subtypes further 
demonstrated that the rare drivers predicted by DawnRank may provide new insights into the 
molecular explanations of cancer subtypes with higher tumor heterogeneity. 
One potential limitation of the current DawnRank method is that we still largely rely on 
known molecular interaction network. Such network information is still incomplete, which may 
create false negatives in DawnRank’s prediction. In addition, currently the overall network 
information we use in DawnRank is not cancer-type specific or patient-specific. Therefore, some 
of the network level interactions and perturbations specific to certain cancer subtypes or patient 
samples may be obscured by this approach. Another potential limitation is that DawnRank 
detects only potential drivers that alter the expression of other genes. However, this may not be 
the case for all drivers. In addition, some of the predictions from our method could potentially be 
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caused by passenger mutations that coincidentally change the expression of downstream genes. 
In those cases, it may be useful to additionally utilize cohort and functional-impact based 
methods such as OncodriveFM. As the community continues to refine our understanding of the 
interaction networks and cancer driver genes, we expect that DawnRank’s ability to predict 
driver alterations would also improve.  
Our method provides a unique solution to predict potential driver genes in cancer. 
However, the computationally predicted personalized drivers should not be over-interpreted 
before additional experimental evidence becomes available. To fully validate such computational 
predictions, both in vitro and in vivo experimental validations would be needed to 
comprehensively assess the tumorigenic potentials of predicted drivers in individual patients. 
Nevertheless, our method provides a reliable solution to prioritize such follow-up experimental 
validations. Taken together, our personalized approach is promising to discover potential causal 
generic variants that would be otherwise obscured by tumor heterogeneity. The personalized 
framework may help determine the optimal treatment strategy for each patient through 
individualized assessment based on the molecular signatures of their cancers. 
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CHAPTER 5 
FIGURES 
 
Figure 1: Overview of the DawnRank Method 
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Figure 2: A comparison of the precision, recall, and F1-scores for the top ranking genes in 
DawnRank and DriverNet. The X-axis represents the number of top ranking genes involved in 
the precision, recall, and F1 score calculation. The Y-axis represents the score of the given 
metric. 
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Figure 3: A comparison of the precision, recall, and F1 scores for the top ranking genes in 
DawnRank, DriverNet, and PARADIGM-Shift on a small network (defined from the KEGG 
database). The X-axis represents the number of top ranking genes involved in the precision, 
recall, and F1 score calculation. The Y-axis represents the score of the given metric. 
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Figure 4 
 
Figure 4: Comparison results using subset of patient samples. The Figure Chows the precision, 
recall, and F1 scores of the DawnRank and DriverNet results in determining known drivers 
among their top 30 genes using a small subset of the patient samples (X-axis) rather than the 
entire cohort. The Y-axis represents the average precision of 10 runs using the subset. The error 
bars show the 1-standard deviation range of each data point. 
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Figure 5 
 
Figure 5: Personalized drivers in TCGA ovarian cancer samples. (A) The darker red/blue entries 
(red for point mutations and blue for CNVs) indicate the personalized drivers that are significant 
and not documented in CGC. The lighter entries are mutations that are not considered as drivers 
by DawnRank in specific samples. The X-axis includes patient samples with a personalized 
driver that is significant and not documented in CGC. On the Y-axis, rare drivers (frequency 
<2%) are in blue and non-rare drivers (frequency >=2%) are in purple. (B) Part of the gene 
interaction network where TRAF6 is involved. The size of the node scales according to the 
DawnRank score in ovarian cancer patient sample TCGA-13-1410 and the color intensity scales 
with differential expression. Note that this Figure Chows the impact of TRAF6 to other genes in 
the network, but not all the edges where TRAF6 is not involved are shown due to space limitation 
(for example, the large number of outgoing edges of TP53). (C) A close-up view of the protein 
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structure of TRAF6 indicates that an amino acid change from the mutation in ovarian cancer 
patient sample TCGA-13-1410 causes substitution of the Arginine (R) to Tryptophan (W). The 
substitution of the mutation occurs in a conserved binding site, and the substitution from a 
charged Arginine to a non-polar aromatic amino acid Tryptophan may suggest a change in the 
substrate binding with the CD40 peptide substrate. 
 
 
 
Figure 6: Distribution of rare drivers (A) and known drivers (B) across four breast cancer 
subtypes. The X-axis describes the frequency cutoffs (1% to 5%). Note that this cutoff is not 
cumulative. The Y-axis shows the proportion of patient samples that have rare drivers within that 
frequency cutoff. 
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APPENDIX A 
LIST OF ABBREVIATIONS 
NGS – Next-generation Sequencing 
CGC – Cancer Gene Census 
TCGA – The Cancer Genome Atlas 
GBM – Glioblastoma multiforme 
OV – Ovarian Cancer 
BRCA – Breast Cancer  
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APPENDIX B 
SUPPLEMENTAL INFORMATION 
B.1 Dynamic Damping Factor vs. Static Damping Factor 
We compared DawnRank using the dynamic damping factor (see Methods section) to a 
PageRank-like algorithm with a static damping factor to determine the impact of our method 
over traditional PageRank-like methods. Precision, recall, and F1 score were based on the top N 
genes where N ranges from 1 to 100. The PageRank-like static damping factor used the 
PageRank-suggested value 0.85, whereas the DawnRank dynamic damping factor used a free 
parameter trained 𝜇 of 3 (see Methods in the main text). We evaluated the precision and recall 
scores to compare the quality of the static damping factor and the dynamic damping factor.  
In evaluating both damping factors, the dynamic damping factor has a higher precision, 
recall, and F1 score than the static damping factor in all three cancers. See Supplementary Figure 
C1. In OV and BRCA, many known drivers such as NF1, BRCA2, RB1, and APC in OV and 
PIK3CA, MAP2K4, and PIK3R1 in BRCA were ranked in the top 10 using the dynamic damping 
factor, and they were not accounted for using the static damping factor. In GBM, the dynamic 
damping factor performs slightly worse regarding the top 10 genes as several driver genes such 
as TP53 and EGFR are ranked in the top 15 rather than the top 10. 
Overall, the result shows that the dynamic damping factor is helpful in determining 
known driver mutations more precisely than the static damping factor. 
An illustration of the zero-one gap problem is shown in Supplementary Figure C2. In 
Supplementary Figure C2, there is a network with six nodes linking to a center node. Each of the 
outer nodes linking to the center node has the same ranking. In the PageRank-like method with a 
static damping factor, the rank of a node depends on the rank of outgoing nodes, and therefore 
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genes that have more outgoing edges would have a higher score. However, when static damping 
factor is used, adding outgoing edges from the central node provides a counterintuitive result, not 
increasing the rank of the central node while also decreasing the ranks of the outer nodes. This is 
due to the difference in the damping factor between a node with no incoming edge and a node 
with one incoming edge is very large (a difference of a damping factor 0 and 0.85). This tends to 
lead to unstable rankings. The DawnRank dynamic damping factor correctly stabilizes the rank 
of the outer nodes while augmenting the rank of the central node. The change in rankings 
demonstrates the importance of using a dynamic damping factor. As shown earlier, we also 
compared the results on using dynamic damping factor and static damping factor based on 
TCGA data, and demonstrated that the dynamic damping factor can help identify more drivers 
than the static damping factor (Supplementary Figure C1).  
B.2 DawnRank Proof of Convergence 
The DawnRank formula is shown in Equation 1 below: 
𝑟$( = (1 − 𝑑$)𝑓$ + 𝑑$ 𝐴$#𝑟#(G*𝑑𝑒𝑔#2#3* , 1 ≤ 𝑗 ≤ 𝑁 (1) 
To prove that the convergence time is small, let us define 𝑟$∗ to be the true ranking of any gene j. 
Therefore the true rank of any gene must satisfy the DawnRank formula in (1) exactly.  
𝑟$∗ = (1 − 𝑑$)𝑓$ + 𝑑$ 𝐴$#𝑟#∗𝑑𝑒𝑔#2#3* , 1 ≤ 𝑗 ≤ 𝑁 (2) 
To determine the convergence, we calculate the error of DawnRank at each time point t 
compared to the true result. The error rate of gene j will be defined as the sum of the absolute 
difference between each ranking of gene j:  
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𝐸𝑟𝑟 𝑡 = 𝑟$( − 𝑟$∗$  (3) 
To calculate the error, we calculate	𝑟$( − 𝑟$∗: 
𝑟$( − 𝑟$∗ = 𝑑$ 𝐴$#𝑟#(G*𝑑𝑒𝑔#2#3* − 𝑑$ 𝐴$#𝑟#∗𝑑𝑒𝑔#2#3*  (4) 
Therefore, by way of the triangle inequality 𝑟$( − 𝑟$∗ : 
𝑟$( − 𝑟$∗ ≤ 𝑑$ 𝐴$#|𝑟#(G* − 𝑟#∗|𝑑𝑒𝑔#2#3*  (5) 
And the error rate will become the summation for all j.  
𝐸𝑟𝑟 𝑡 = 𝑟$( − 𝑟$∗$ ≤ 𝑑$$ 𝐴$#|𝑟#(G* − 𝑟#∗|𝑑𝑒𝑔#2#3*  (6) 
 
This becomes 
𝐸𝑟𝑟 𝑡 ≤ (𝑑$𝐴$#)$ |𝑟#(G* − 𝑟#∗|𝑑𝑒𝑔#2#3*  (7) 
 
Since 𝑑𝑒𝑔u = 𝐴$#2$3*  and 0 ≤ 𝑑$ ≤ 1 for all instances of j: (𝑑$𝐴$#)$ (𝐴$#)$ ≤ 1 (8) 
We have 
𝐸𝑟𝑟 𝑡 ≤ (𝑑$𝐴$#)$ 𝑟#(G* − 𝑟#∗(𝐴$#)$2#3* ≤ 𝐸𝑟𝑟(𝑡 − 1) (9) 
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Unless the damping factor for each j is equal to 1, the error will decrease at a compound rate. 
Therefore given enough iterations, the 𝐸𝑟𝑟 𝑡  will eventually approach 0. In our damping factor: 𝑑# = 𝑑𝑒𝑔# (𝑑𝑒𝑔# + 𝜇) , where 𝜇 = 3, the damping factor will always be less than 1 for all 
genes. Therefore, for our iteration of DawnRank, the algorithm will converge at a compound 
rate. 
B.3 Parameter Training 
We trained two parameters in our model, the µ free parameter used to calculate the damping 
factor	𝑑# = 𝑑𝑒𝑔# (𝑑𝑒𝑔# + 𝜇), and the	𝛿 parameter used in the Condorcet rank-aggregation in 
order to account for missing data in certain pairwise comparisons. We performed the parameter 
training over 100 random patient samples using the small network of the KEGG pathways of 
1,492 genes. This network was used to avoid using the same data to train the model and to run 
the analysis. This model was run over a 10-fold cross validation to determine the most reliable 
results. 
We calculated µ by running the DawnRank algorithm using the data and network 
described in the main text over various empirically chosen µ. We selected the µ that presented 
the highest average rank for common driver genes from CGC. Our results show that the µ 
parameter has a peak at µ=3 where the average percentile rank of known driver genes is in the 
72.7 percentile. Known drivers are driver genes in CGC. In Supplementary Figure C4, we show 
that µ=3 parameter contains the highest average rank of common driver genes with downward 
trends as µ both increases and decreases, so we set µ=3. DawnRank scores are based on both 
differential expression and a network connectivity, whose weight is determined by the damping 
factor. A high µ value lowers the impact of the network in DawnRank, and a low µ puts too 
much emphasis on the network and not enough on the differential expression. 
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 We then applied the Condorcet rank aggregation to our DawnRank trial runs using the 
µ=3. Since the 𝛿 is a value from 0 and 1, we ran the Condorcet rank aggregation for all values of 𝛿 from 0 and 1 with an increment of 0.05. We selected the parameter that maximized the 
precision with respect to genes in CGC for the top 10 mutated genes within the randomly 
selected patient samples. This process was run 10 times, and the precision results for the 10 runs 
are shown in the Supplementary Figure C5 below. We can see from the figure that the precision 
with respect to CGC is maximized at 𝛿 = 0.85. 
B.4 Comparison with Summary Statistics  
In addition to comparing DawnRank results with well-established and known methods, we also 
compared DawnRank rankings to simple metrics. We compared DawnRank’s rankings to the 
rankings based on the results: (1) if we only used connectivity of the genes; (2) if we only used 
differential expression of the genes; and (3) if we only used the maximum downstream 
differential expression, i.e., ranking genes by the maximum differential expression among all 
outgoing genes. We used the same precision-recall evaluation metrics. The results showed that 
none of the three metrics performs well by themselves, suggesting that it is necessary for 
DawnRank to use a combination of connectivity and differential expression to calculate its rank 
(Supplementary Figure C12).  
B.4.1 Comparison against tumor quality and survival rate 
We examined potential clinical factors that may show relationships with the DawnRank output. 
We compared the DawnRank scores with tumor quality and survival rate. With tumor quality, we 
found no significant correlation with DawnRank scores. For each patient in the three cancer 
types, we determined the Pearson correlation of the tumor nuclei percentage with both the 
average rank of driver mutations and the variance of the ranks of the driver mutations. This 
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would test whether or not the tumor nuclei percentage was correlated with either the rank of 
driver mutations, indicating that more tumor quality leads to more significant driver, or the 
variance of the driver mutations, indicating that tumor quality raises the variation among drivers. 
The resulting correlation, however, was low (each of the correlations for driver means and 
variances with tumor nuclei percentages was between 0.01 and -0.01) with the tumor quality 
having little relationship with the mean or variance of drivers. One potential reason behind this 
lack of correlation is the fact that TCGA has already required tumors should have at least 60% 
tumor nuclei for data from NGS platforms (and 80% for previous tumor samples). 
 We then examined the relationship between the DawnRank scores and the survival rate. 
We took advantage of the inter-tumor heterogeneity of the tumors, and the resulting DawnRank 
scores were used as variables to build a consensus hierarchical co-clustering model using Wards 
linkage to separate the patients into potential subtypes. We compared our results to the gene-
expression based GBM subtypes: Classical, Proneural, Neural, and Mesenchymal [1]. We chose 
to analyze GBM because it has both gene expression based subtypes and lower and more 
variable survival rates [2]. The results are shown in Supplementary Figure C13. Using a log-rank 
test, we found that the DawnRank hierarchical clustering separated the subtypes by survival time 
even more accurately than that of conventional gene-expression subtypes (p=0.0044 and 
p=0.131).  
B.4.2 Comparison against mutation rate 
One factor that may determine the number of driver mutations predicted by DawnRank could be 
the mutation rate itself. On average, there are 4.24 drivers per patient in GBM, 5.89 drivers in 
BRCA, and 6.05 drivers in OV, within the range of the 2-8 mutations expected in solid tumors 
[3]. The total number of alterations (mutation plus copy number) in each of the three cancers is 
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7,876, 10,950, and 17,189, respectively. Therefore, even though OV has higher mutation rate, the 
number of drivers only increases a little, suggesting the robustness of our method. To examine 
the DawnRank score in a more extreme case, we applied our method to the lung cancer data in 
TCGA, including 22,789 mutations across 152 samples. We found that the average number of 
drivers in lung cancer patients is 7.18. Therefore, even with the large number of mutations in 
lung cancer, DawnRank still predicts the reasonable number of drivers, further suggesting the 
robustness of the method. We also plotted the number of predicted drivers against the total 
number of mutations for individual patients in Supplementary Figure C14. We observed that as 
the number of mutations increases, the number of predicted drivers in an individual sample 
increases at a much lower rate until it reaches a plateau, further suggesting the robustness of our 
method. 
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APPENDIX C 
SUPPLEMENTAL FIGURES 
 
 
Figure C1: A comparison of the precision, recall, and F1 score for the top ranked genes when 
using the static damping factor (in original PageRank) and the dynamic damping factor (in 
DawnRank). The X-axis represents the number of top ranked genes involved in the precision, 
recall and F1 score calculation, and the Y-axis represents the score of the given metric.  
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Figure C2: A toy example showing the effect of using dynamic damping factor. (A) Original 
network with one central node and six outer nodes. (B) When static damping factor is used, after 
adding the outgoing edges (in red) from the central node, the ranking of the central node does not 
change and the ranking of the outer nodes decreases. (C) When dynamic damping factor is used 
(as in DawnRank), after adding the outgoing edges from the central node, the ranking of the 
central node increases (as expected) and the ranking of the outer nodes does not change (as 
expected). 
 
  
(A) (B) (C)
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Figure C3: The static versus the dynamic damping factor change over the number of inlinks (i.e. 
incoming edges). 
 
  
Figure C4: The training results for various µ parameters when looking at the average rank of 
common driver genes. The µ that provides the highest average rank is 3. 
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Figure C5 The training results for various 𝛿 parameters when looking at the average precision of 
the top 10 rank-aggregated genes with respect to CGC. The 𝛿 is maximized at 0.85 with a 
precision of 0.59. 
●
●
●
●
● ● ● ●
●
●
● ●
●
●
●
●
●
● ●
●
0.40
0.45
0.50
0.55
0.25 0.50 0.75 1.00
Proposed Delta
Av
er
ag
e 
Pr
ec
isi
on
 fo
r t
op
 1
0 
Ge
ne
s
Free Parameter Training for the Condorceet Vote Aggregation
50	
	
 
 
Figure C6: A close-up view of the protein structure of PDPK1 indicates that an amino acid 
change from the mutation causes substitution of the Glycine (G) to Arginine (R) in TCGA 
Ovarian Cancer samples TCGA-13-0751 (DawnRank score 98.14 percentile). The substitution is 
in a loop between 2 beta strands, and occurs close to the binding site for the substrate 
Ins(1,3,4,5)P4, indicating a potential interaction of the positively charged R-group of Arginine 
and a phosphate group.  
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Figure C7: A visualization of the top driver CNVs in BRCA, GBM, and OV. The X-axis 
represents the top genes (in order of rank), and the Y-axis represents the copy number changes. 
The labels of known drivers are shown in blue.  
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Figure C8: Personalized drivers in TCGA GBM samples. The darker red/blue entries (red for 
point mutations and blue for CNVs) indicate the personalized drivers that are significant and not 
documented in CGC. The lighter entries are mutations that are not considered as drivers by 
DawnRank in specific samples. The X-axis includes patient samples with a personalized driver 
that is significant and not documented in CGC. On the Y-axis, rare drivers (frequency < 2%) are 
in blue and non-rare drivers (frequency >= 2%) are in purple. 
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Figure C9: Personalized drivers in TCGA BRCA samples. The darker red/blue entries (red for 
point mutations and blue for CNVs) indicate the personalized drivers that are significant and not 
documented in CGC. The lighter entries are mutations that are not considered as drivers by 
DawnRank in specific samples. The X-axis includes patient samples with a personalized driver 
that is significant and not documented in CGC. On the Y-axis, rare drivers (frequency < 2%) are 
in blue and non-rare drivers (frequency >= 2%) are in purple. 
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Figure C10: A comparison of the precision, recall, and F1-scores for the top ranking genes in 
DawnRank, CHASM and OncodriveFM. The X-axis represents the number of top ranking genes 
involved in the precision, recall, and F1 score calculation. The Y-axis represents the score of the 
given metric.  
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Figure C11: A comparison of the precision, recall, and F1-scores for the top ranking genes in 
DawnRank, DriverNet, and PARADIGM-Shift using the Pan-Cancer predicted drivers based on 
[4]. The X-axis represents the number of top ranking genes involved in the precision, recall, and 
F1 score calculation. The Y-axis represents the score of the given metric.  
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Figure C12: A comparison of the precision, recall, and F1-scores for the top ranking genes in 
DawnRank compared to three summary statistics: differential expression only, connectivity, and 
maximum downstream differential expression (MaxExp). The X-axis represents the number of 
top ranking genes involved in the precision, recall, and F1 score calculation. The Y-axis 
represents the score of the given metric.  
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Figure C13: A Kaplan-Meier survival plot showing the survival rates of four clusters derived 
from using GBM DawnRank scores (left), as compared to expression based clustering (right). 
The X-axis represents the days until death and the Y-axis represents the proportion of living 
patients. 
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Figure C14: A plot illustrating the trend between the total number of mutations (X-axis) and the 
number of significant DawnRank drivers (Y-axis). The intensity of each point represents the 
number of patients at the coordinate. The line in blue is the LOESS curve. 
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